Lopinavir and Ritonavir
In patients infected with 2019-nCoV, clinical trials (e.g.,
ChiCTR2000029539) were initiated to study HIV protease inhibitors such
as Lopinavir and Ritonavir. Lopinavir and Ritonavir were initially
suspected to inhibit SARS and MERS 3-chymotrypsin-like protease and
seemedto be correlated in a non-randomized open-label trial 2, with
improved clinical outcomes of SARS patients. Lopinavir/Ritonavir
(dosages: 200mg/50mg/capsule,2 capsules each time,2 times/day, by oral
administration, treated no more than 10 days) guidelines (version 6) for
treatment of COVID-19. It was revealed that Lopinavir and Ritonavir were
associated with significant clinical benefit (less adverse clinical
outcomes) among SARS-CoV patients [43]. The combination of Lopinavir
and Ritonavir is currently a recommended antivirus regimen approved by
the National Health Commission of the People’s Republic of China in the
latest form of Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV
(version 5) [44].